Compugen (CGEN)
NASDAQ:CGEN
Want to see CGEN full AI Analyst Report?
CGEN Stock Chart & Stats
$2.82
-$0.04(-2.19%)
At close: 4:00 PM EST
$2.82
-$0.04(-2.19%)
Day’s Range― - ―
52-Week Range$1.30 - $3.24
Previous CloseN/A
Volume276.40K
Average Volume (3M)598.73K
Market Cap
$250.57M
Enterprise Value$255.25M
Total Cash (Recent Filing)$145.64M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 11, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding94,553,190
10 Day Avg. Volume655,429
30 Day Avg. Volume598,725
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.96
P/FCF Ratio4.56
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda7.65
Forecast
1Y Price Target
$4.75Price Target Upside68.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$11.22M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Cash RunwayAstraZeneca's significant upfront payment for a portion of royalty rights strengthened Compugen's balance sheet and materially extended the cash runway, lowering near-term financing pressure.
Clinical DifferentiationCompugen's Fc-reduced TIGIT design is engineered to preserve tumor-killing T cells, and clinical signals of durable responses when COM701 is combined with TIGIT and PD-1 therapies suggest meaningful therapeutic differentiation.
Strategic PartnershipAstraZeneca's major commitment to develop a bispecific antibody using Compugen's TIGIT component across late-stage cancer trials provides clear partner validation and supports broader adoption of the platform.
Bears Say
Market Sentiment And Revenue ConcentrationPersistent negative sentiment toward the TIGIT drug class combined with reliance on a one-time payment for revenue may weigh on investor confidence and highlight concerns about revenue concentration.
Safety And Class RiskEarlier failures in the TIGIT class linked to depletion of effector T cells create heightened safety scrutiny and raise the development bar for new TIGIT entrants.
Compugen News
CGEN FAQ
What was Compugen’s price range in the past 12 months?
Compugen lowest stock price was $1.29 and its highest was $3.23 in the past 12 months.
What is Compugen’s market cap?
Compugen’s market cap is $250.57M.
When is Compugen’s upcoming earnings report date?
Compugen’s upcoming earnings report date is Aug 11, 2026 which is in 74 days.
How were Compugen’s earnings last quarter?
Compugen released its earnings results on May 18, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.01.
Is Compugen overvalued?
According to Wall Street analysts Compugen’s price is currently Undervalued.
Does Compugen pay dividends?
Compugen does not currently pay dividends.
What is Compugen’s EPS estimate?
Compugen’s EPS estimate is -0.08.
How many shares outstanding does Compugen have?
Compugen has 94,553,190 shares outstanding.
What happened to Compugen’s price movement after its last earnings report?
Compugen reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went up 4%.
Which hedge fund is a major shareholder of Compugen?
Currently, no hedge funds are holding shares in CGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compugen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (68.44% Upside)
$4.75 (68.44% Upside)
Blogger Sentiment
Neutral
CGEN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.00%
12-Months-Change
Fundamentals
Return on Equity
47.72%
Trailing 12-Months
Asset Growth
26.35%
Trailing 12-Months
Company Description
Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
CGEN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful clinical and strategic progress: initiation and active enrollment of the MAIA-ovarian trial for COM701 with an interim PFS readout expected in Q1 2027, advancing partnered programs (AstraZeneca's rilvegostomig and Gilead's GS-0321) with substantial potential milestones, continued discovery momentum from the Unigen platform, and a solid cash position (~$134.9M) providing runway into 2029. Offsetting these positives were modest near-term financials (Q1 revenue down ~4.4% to $2.2M), higher R&D spending (+~19%) and a slightly larger net loss (+~6.9%), plus dependence on partner milestones and uncertainty around trial outcomes and enrollment details. On balance, the call portrays a company making strategic clinical and partnership advances while investing into development, with manageable but notable near-term financial and execution risks.View all CGEN earnings summariesCGEN Stock 12 Month Forecast
Average Price Target
$4.75
▲(68.44% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
3.71% Mutual Funds
8.83% Other Institutional Investors
85.88% Public Companies and
Individual Investors